Benitec Biopharma Inc
BNTC
Get informed when a big investor buys or sells
+ FollowMarket Cap$308.5M
Close$
$2.70
69.9% downside
Current Fair Value
69.9% downsideOvervalued by 69.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $308.50 Million |
|---|---|
| Enterprise Value | $129.29 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.98 |
| Beta | 0.27 |
| Outstanding Shares | 46,558,162 |
Return
| Return on Equity | -25.73% |
|---|---|
| Return on Assets | -24.94% |
| Return on Invested Capital | -28.88% |
Valuation & Multiples
| P/E Ratio | -9.16 |
|---|---|
| PEG | 44.33 |
| Price to Sales | - |
| Price to Book Ratio | 2.99 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -2.52 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 30, 2026
EPS Estimate
$-0.28
Average shareholder expectationRevenue Estimate
$13.70 M
Average shareholder expectationNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
$-0.27
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 67.25%▲ 1.47% |
|---|---|
| Total Invested | $444.30M▲ 28.40% |
| Investors Holding | 89▲ 1.00% |
ESG Score
No data